1,762 results on '"Radiation necrosis"'
Search Results
2. Laser Ablation After Stereotactic Radiosurgery (LAASR)
- Published
- 2024
3. Successful pain control with add-on methadone for refractory neuropathic pain due to radiation necrosis in pontine metastatic lesion: a case report.
- Author
-
Kurosaki, Fumio, Takigami, Ayako, Takeuchi, Mitsue, Shimizu, Atsushi, Tamba, Kaichiro, Bando, Masashi, and Maemondo, Makoto
- Subjects
- *
METHADONE treatment programs , *NEURALGIA , *MORPHINE , *NECROSIS , *OXYCODONE , *ANALGESICS , *SURGICAL complications , *BRAIN stem , *LUNG cancer - Abstract
Background: Central pain, characterized by neuropathic pain, can manifest due to injury to the superior spinothalamic tract. The brainstem includes sensory and motor pathways as well as nuclei of the cranial nerves, and therefore cancer metastasis in the region requires early intervention. Although stereotactic radiosurgery (SRS) is commonly employed for the treatment of brain metastasis, it poses risks of late complications like radiation necrosis (RN). RN exacerbates the progression of brain lesions within the irradiated area, and in the brainstem, it can damage multiple nerves, including the superior spinothalamic tract. Central neuropathic pain is often intractable and empirically managed with a combination of conventional drugs, such as serotonin-norepinephrine reuptake inhibitors (SNRIs) and anticonvulsants. However, their efficacy is often limited, leading to a decline in performance status (PS) and quality of life (QOL). Case presentation: We present the case of a 53-year-old man diagnosed with stage IV lung cancer, referred to our palliative care team for managing severe central pain resulting from SRS-related RN in the pons. Despite administration of opioids, including oxycodone and hydromorphone, and adjuvant analgesics, the patient continued to require frequent use of immediate-release opioids. The addition of methadone alone proved successful in achieving optimal pain control. Conclusions: Provided that RN in the brainstem can lead to intractable neuropathic pain, it is advisable to avoid SRS for brainstem metastasis when possible. Add-on methadone should be considered as a viable pain management medication for patients experiencing unresolved central pain. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Comparative evaluation of outcomes amongst different radiosurgery management paradigms for patients with large brain metastasis.
- Author
-
Kutuk, Tugce, Zhang, Yanjia, Akdemir, Eyub Yasar, Yarlagadda, Sreenija, Tolakanahalli, Ranjini, Hall, Matthew D., La Rosa, Alonso, Wieczorek, DJay J., Lee, Yongsook C., Press, Robert H., Appel, Haley, McDermott, Michael W., Odia, Yazmin, Ahluwalia, Manmeet S., Gutierrez, Alonso N., Mehta, Minesh P., and Kotecha, Rupesh
- Abstract
Introduction: This study compares four management paradigms for large brain metastasis (LMB): fractionated SRS (FSRS), staged SRS (SSRS), resection and postoperative-FSRS (postop-FSRS) or preoperative-SRS (preop-SRS). Methods: Patients with LBM (≥ 2 cm) between July 2017 and January 2022 at a single tertiary institution were evaluated. Primary endpoints were local failure (LF), radiation necrosis (RN), leptomeningeal disease (LMD), a composite of these variables, and distant intracranial failure (DIF). Gray's test compared cumulative incidence, treating death as a competing risk with a random survival forests (RSF) machine-learning model also used to evaluate the data. Results: 183 patients were treated to 234 LBMs: 31.6% for postop-FSRS, 28.2% for SSRS, 20.1% for FSRS, and 20.1% for preop-SRS. The overall 1-year composite endpoint rates were comparable (21 vs 20%) between nonoperative and operative strategies, but 1-year RN rate was 8 vs 4% (p = 0.012), 1-year overall survival (OS) was 48 vs. 69% (p = 0.001), and 1-year LMD rate was 5 vs 10% (p = 0.052). There were differences in the 1-year RN rates (7% FSRS, 3% postop-FSRS, 5% preop-SRS, 10% SSRS, p = 0.037). With RSF analysis, the out-of-bag error rate for the composite endpoint was 47%, with identified top-risk factors including widespread extracranial disease, > 5 total lesions, and breast cancer histology. Conclusion: This is the first study to conduct a head-to-head retrospective comparison of four SRS methods, addressing the lack of randomized data in LBM literature amongst treatment paradigms. Despite patient characteristic trends, no significant differences were found in LF, composite endpoint, and DIF rates between non-operative and operative approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Successful pain control with add-on methadone for refractory neuropathic pain due to radiation necrosis in pontine metastatic lesion: a case report
- Author
-
Fumio Kurosaki, Ayako Takigami, Mitsue Takeuchi, Atsushi Shimizu, Kaichiro Tamba, Masashi Bando, and Makoto Maemondo
- Subjects
Central pain ,Brainstem metastasis ,Stereotactic radiosurgery ,Radiation necrosis ,Methadone ,Special situations and conditions ,RC952-1245 - Abstract
Abstract Background Central pain, characterized by neuropathic pain, can manifest due to injury to the superior spinothalamic tract. The brainstem includes sensory and motor pathways as well as nuclei of the cranial nerves, and therefore cancer metastasis in the region requires early intervention. Although stereotactic radiosurgery (SRS) is commonly employed for the treatment of brain metastasis, it poses risks of late complications like radiation necrosis (RN). RN exacerbates the progression of brain lesions within the irradiated area, and in the brainstem, it can damage multiple nerves, including the superior spinothalamic tract. Central neuropathic pain is often intractable and empirically managed with a combination of conventional drugs, such as serotonin-norepinephrine reuptake inhibitors (SNRIs) and anticonvulsants. However, their efficacy is often limited, leading to a decline in performance status (PS) and quality of life (QOL). Case presentation We present the case of a 53-year-old man diagnosed with stage IV lung cancer, referred to our palliative care team for managing severe central pain resulting from SRS-related RN in the pons. Despite administration of opioids, including oxycodone and hydromorphone, and adjuvant analgesics, the patient continued to require frequent use of immediate-release opioids. The addition of methadone alone proved successful in achieving optimal pain control. Conclusions Provided that RN in the brainstem can lead to intractable neuropathic pain, it is advisable to avoid SRS for brainstem metastasis when possible. Add-on methadone should be considered as a viable pain management medication for patients experiencing unresolved central pain.
- Published
- 2024
- Full Text
- View/download PDF
6. Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know.
- Author
-
Young, Jacob, Al-Adli, Nadeem, Scotford, Katie, Berger, Mitchel, and Cha, Soonmee
- Subjects
glioblastoma ,glioma ,oncology ,radiation necrosis ,treatment-related effects ,true progression ,tumor ,pseudoprogression ,Humans ,Glioblastoma ,Neurosurgeons ,Brain Neoplasms ,Disease Progression ,Magnetic Resonance Imaging - Abstract
Management of patients with glioblastoma (GBM) is complex and involves implementing standard therapies including resection, radiation therapy, and chemotherapy, as well as novel immunotherapies and targeted small-molecule inhibitors through clinical trials and precision medicine approaches. As treatments have advanced, the radiological and clinical assessment of patients with GBM has become even more challenging and nuanced. Advances in spatial resolution and both anatomical and physiological information that can be derived from MRI have greatly improved the noninvasive assessment of GBM before, during, and after therapy. Identification of pseudoprogression (PsP), defined as changes concerning for tumor progression that are, in fact, transient and related to treatment response, is critical for successful patient management. These temporary changes can produce new clinical symptoms due to mass effect and edema. Differentiating this entity from true tumor progression is a major decision point in the patients management and prognosis. Providers may choose to start an alternative therapy, transition to a clinical trial, consider repeat resection, or continue with the current therapy in hopes of resolution. In this review, the authors describe the invasive and noninvasive techniques neurosurgeons need to be aware of to identify PsP and facilitate surgical decision-making.
- Published
- 2023
7. Hybrid Positron Emission Tomography and Magnetic Resonance Imaging Guided Microsurgical Management of Glial Tumors: Case Series and Review of the Literature.
- Author
-
Caglar, Yusuf Sukru, Buyuktepe, Murat, Sayaci, Emre Yagiz, Dogan, Ihsan, Bozkurt, Melih, Peker, Elif, Soydal, Cigdem, Ozkan, Elgin, and Kucuk, Nuriye Ozlem
- Subjects
- *
GLIOMAS , *MAGNETIC resonance imaging , *POSITRON emission tomography , *INTRACRANIAL tumors , *LITERATURE reviews - Abstract
In this case series, we aimed to report our clinical experience with hybrid positron emission tomography (PET) and magnetic resonance imaging (MRI) navigation in the management of recurrent glial brain tumors. Consecutive recurrent neuroglial brain tumor patients who underwent PET/MRI at preoperative or intraoperative periods were included, whereas patients with non-glial intracranial tumors including metastasis, lymphoma and meningioma were excluded from the study. A total of eight patients (mean age 50.1 ± 11.0 years) with suspicion of recurrent glioma tumor were evaluated. Gross total tumor resection of the PET/MRI-positive area was achieved in seven patients, whereas one patient was diagnosed with radiation necrosis, and surgery was avoided. All patients survived at 1-year follow-up. Five (71.4%) of the recurrent patients remained free of recurrence for the entire follow-up period. Two patients with glioblastoma had tumor recurrence at the postoperative sixth and eighth months. According to our results, hybrid PET/MRI provides reliable and accurate information to distinguish recurrent glial tumor from radiation necrosis. With the help of this differential diagnosis, hybrid imaging may provide the gross total resection of recurrent tumors without harming eloquent brain areas. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. The Use of Apparent Diffusion Coefficient Values for Differentiating Bevacizumab-Related Cytotoxicity from Tumor Recurrence and Radiation Necrosis in Glioblastoma.
- Author
-
Khalaj, Kamand, Jacobs, Michael A., Zhu, Jay-Jiguang, Esquenazi, Yoshua, Hsu, Sigmund, Tandon, Nitin, Akhbardeh, Alireza, Zhang, Xu, Riascos, Roy, and Kamali, Arash
- Subjects
- *
GLIOMAS , *CANCER relapse , *DATA analysis , *BEVACIZUMAB , *APOPTOSIS , *NECROSIS , *TREATMENT effectiveness , *MAGNETIC resonance imaging , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *TUMOR markers , *LONGITUDINAL method , *STATISTICS , *SENSITIVITY & specificity (Statistics) , *DISEASE progression - Abstract
Simple Summary: This study investigates an imaging method for distinguishing different lesions in brain cancer patients using MRI scans. Glioblastoma is a highly aggressive brain tumor, and it is crucial to differentiate between actual tumor recurrence, radiation-induced damage, and side effects from a common treatment called Bevacizumab. Traditional MRI techniques often struggle to make these distinctions, leading to challenges in treatment decisions. This study explores the use of a specific MRI measurement, called Apparent Diffusion Coefficient (ADC) values, to improve diagnostic accuracy. By identifying unique patterns in ADC values, this method could help better determine the nature of brain lesions, ultimately leading to more precise and effective treatment plans for glioblastoma patients. Objectives: Glioblastomas (GBM) are the most common primary invasive neoplasms of the brain. Distinguishing between lesion recurrence and different types of treatment related changes in patients with GBM remains challenging using conventional MRI imaging techniques. Therefore, accurate and precise differentiation between true progression or pseudoresponse is crucial in deciding on the appropriate course of treatment. This retrospective study investigated the potential of apparent diffusion coefficient (ADC) map values derived from diffusion-weighted imaging (DWI) as a noninvasive method to increase diagnostic accuracy in treatment response. Methods: A cohort of 21 glioblastoma patients (mean age: 59.2 ± 11.8, 12 Male, 9 Female) that underwent treatment with bevacizumab were selected. The ADC values were calculated from the DWI images obtained from a standardized brain protocol across 1.5-T and 3-T MRI scanners. Ratios were calculated for rADC values. Lesions were classified as bevacizumab-induced cytotoxicity based on characteristic imaging features (well-defined regions of restricted diffusion with persistent diffusion restriction over the course of weeks without tissue volume loss and absence of contrast enhancement). The rADC value was compared to these values in radiation necrosis and recurrent lesions, which were concluded in our prior study. The nonparametric Wilcoxon signed rank test with p < 0.05 was used for significance. Results: The mean ± SD age of the selected patients was 59.2 ± 11.8. ADC values and corresponding mean rADC values for bevacizumab-induced cytotoxicity were 248.1 ± 67.2 and 0.39 ± 0.10, respectively. These results were compared to the ADC values and corresponding mean rADC values of tumor progression and radiation necrosis. Significant differences between rADC values were observed in all three groups (p < 0.001). Bevacizumab-induced cytotoxicity had statistically significant lower ADC values compared to both tumor recurrence and radiation necrosis. Conclusion: The study demonstrates the potential of ADC values as noninvasive imaging biomarkers for differentiating recurrent glioblastoma from radiation necrosis and bevacizumab-induced cytotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Surgery of enlarging lesions after stereotactic radiosurgery for brain metastases in patients with non‐small cell lung cancer with oncogenic driver mutations frequently reveals radiation necrosis: case series and review.
- Author
-
Zhou, Fang, Jiang, Leilei, Sun, Xuankai, Wang, Zhen, Feng, Jialin, Liu, Ming, and Ma, Zhao
- Subjects
- *
STEREOTAXIC techniques , *NON-small-cell lung carcinoma , *STEREOTACTIC radiosurgery , *DEEP brain stimulation , *PROTEIN-tyrosine kinase inhibitors , *NECROSIS , *MAGNETIC resonance imaging - Abstract
In brain metastases, radiation necrosis (RN) is a complication that arises after single or multiple fractionated stereotactic radiosurgery (SRS/FSRS), which is challenging to distinguish from local recurrence (LR). Studies have shown increased RN incidence rates in non‐small cell lung cancer (NSCLC) patients with oncogenic driver mutations (ODMs) or receiving tyrosine kinase inhibitors (TKIs). This study investigated enlarging brain lesions following SRS/FSRS, for which additional surgeries were performed to distinguish between RN and LR. We investigated seven NSCLC patients with ODMs undergoing SRS/FSRS for BM and undergoing surgery for suspicion of LR on MRI imaging. Descriptive statistics were performed. Among the seven patients, six were EGFR+, while one was ALK+. The median irradiation dose was 30 Gy (range, 20–35 Gy). The median time to develop RN after SRS/FSRS was 11.1 months (range: 6.3–31.2 months). Moreover, gradually enlarging lesions were found in all patients after 6 months post‐SRS/FSR. Brain radiation necrosis was pathologically confirmed in all the patients. RN should be suspected in NSCLC patients when lesions keep enlarging after 6 months post‐SRS/FSRS, especially for patients with ODMs and receiving TKIs. Further, this case series indicates that further dose reduction might be necessary to avoid RN for such patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Hyperbaric Oxygen Therapy as an Alternative Therapeutic Option for Radiation-Induced Necrosis Following Radiotherapy for Intracranial Pathologies.
- Author
-
Hajikarimloo, Bardia, Kavousi, Shahin, Jahromi, Ghazaleh Ghaffaripour, Mehmandoost, Mahdi, Oraee-Yazdani, Saeed, and Fahim, Farzan
- Subjects
- *
HYPERBARIC oxygenation , *CEREBRAL arteriovenous malformations , *LITERATURE reviews , *NECROSIS , *RADIOTHERAPY , *PATHOLOGY - Abstract
Radiotherapy (RT) is a feasible adjuvant therapeutic option for managing intracranial pathologies. One of the late complications of RT that frequently develops within months following RT is radiation necrosis (RN). Corticosteroids are the first-line therapeutic option for RNs; however, in case of unfavorable outcomes or intolerability, several other options, including bevacizumab, laser interstitial thermal therapy, surgery, and hyperbaric oxygen therapy (HBOT). Our goal was to investigate the feasibility and efficacy of the application of HBOT in RNs following RT and help physicians make decisions based on the latest data in the literature. We provide a comprehensive review of the literature on the current issues of utilization of HBOT in RNs. We included 11 studies with a total of 46 patients who underwent HBOT. Most of the cases were diagnosed with brain tumors or arteriovenous malformations. Improvement was achieved in most of the cases. HBOT is a noninvasive therapeutic intervention that can play a role in adjuvant therapy concurrent with RT and chemotherapy and treating RNs. HBOT resolves the RN through 3 mechanisms, including angiogenesis, anti-inflammatory modulation, and cellular repair. Previous studies demonstrated that HBOT is a feasible and well-tolerated therapeutic option that has shown promising results in improving clinical and radiological outcomes in intracranial RNs. Complications of HBOT are usually mild and reversible. HBOT is a feasible and effective therapeutic option in steroid-refractory RNs and is associated with favorable outcomes and a low rate of side effects. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Expression and distribution of hypoxia‐inducible factor‐1α and vascular endothelial growth factor in comparison between radiation necrosis and tumor tissue in metastatic brain tumor: A case report.
- Author
-
Takagi, Fugen, Furuse, Motomasa, Kuwabara, Hiroko, Kambara, Akihiro, Omura, Naoki, Tanabe, Shogo, Yagi, Ryokichi, Hiramatsu, Ryo, Kameda, Masahiro, Nonoguchi, Naosuke, Kawabata, Shinji, Takami, Toshihiro, Miyatake, Shin‐Ichi, and Wanibuchi, Masahiko
- Abstract
We report the case of a 70‐year‐old woman with metastatic brain tumors who underwent surgical removal of the tumor and radiation necrosis. The patient had a history of colon cancer and had undergone surgical removal of a left occipital tumor. Histopathological evaluation revealed a metastatic brain tumor. The tumor recurred six months after surgical removal, followed by whole‐brain radiotherapy, and the patient underwent stereotactic radiosurgery. Six months later, the perifocal edema had increased, and the patient became symptomatic. The diagnosis was radiation necrosis and corticosteroids were initially effective. However, radiation necrosis became uncontrollable, and the patient underwent removal of necrotic tissue two years after stereotactic radiosurgery. Pathological findings predominantly showed necrotic tissue with some tumor cells. Since the vascular endothelial growth factor (VEGF) and hypoxia‐inducible factor‐1α (HIF‐1α) were expressed around the necrotic tissue, the main cause of the edema was determined as radiation necrosis. Differences in the expression levels and distribution of HIF‐1α and VEGF were observed between treatment‐naïve and recurrent tumor tissue and radiation necrosis. This difference suggests the possibility of different mechanisms for edema formation due to the tumor itself and radiation necrosis. Although distinguishing radiation necrosis from recurrent tumors using MRI remains challenging, the pathophysiological mechanism of perifocal edema might be crucial for differentiating radiation necrosis from recurrent tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Leveraging radiomics and machine learning to differentiate radiation necrosis from recurrence in patients with brain metastases.
- Author
-
Basree, Mustafa M., Li, Chengnan, Um, Hyemin, Bui, Anthony H., Liu, Manlu, Ahmed, Azam, Tiwari, Pallavi, McMillan, Alan B., and Baschnagel, Andrew M.
- Abstract
Objective: Radiation necrosis (RN) can be difficult to radiographically discern from tumor progression after stereotactic radiosurgery (SRS). The objective of this study was to investigate the utility of radiomics and machine learning (ML) to differentiate RN from recurrence in patients with brain metastases treated with SRS. Methods: Patients with brain metastases treated with SRS who developed either RN or tumor reccurence were retrospectively identified. Image preprocessing and radiomic feature extraction were performed using ANTsPy and PyRadiomics, yielding 105 features from MRI T1-weighted post-contrast (T1c), T2, and fluid-attenuated inversion recovery (FLAIR) images. Univariate analysis assessed significance of individual features. Multivariable analysis employed various classifiers on features identified as most discriminative through feature selection. ML models were evaluated through cross-validation, selecting the best model based on area under the receiver operating characteristic (ROC) curve (AUC). Specificity, sensitivity, and F1 score were computed. Results: Sixty-six lesions from 55 patients were identified. On univariate analysis, 27 features from the T1c sequence were statistically significant, while no features were significant from the T2 or FLAIR sequences. For clinical variables, only immunotherapy use after SRS was significant. Multivariable analysis of features from the T1c sequence yielded an AUC of 76.2% (standard deviation [SD] ± 12.7%), with specificity and sensitivity of 75.5% (± 13.4%) and 62.3% (± 19.6%) in differentiating radionecrosis from recurrence. Conclusions: Radiomics with ML may assist the diagnostic ability of distinguishing RN from tumor recurrence after SRS. Further work is needed to validate this in a larger multi-institutional cohort and prospectively evaluate it's utility in patient care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Comparative analysis of bevacizumab and LITT for treating radiation necrosis in previously radiated CNS neoplasms: a systematic review and meta-analysis.
- Author
-
Gecici, Neslihan Nisa, Gurses, Muhammet Enes, Kaye, Brandon, Jimenez, Natasha L. Frontera, Berke, Chandler, Gökalp, Elif, Lu, Victor M., Ivan, Michael E., Komotar, Ricardo J., and Shah, Ashish H.
- Abstract
Purpose: Radiation necrosis (RN) is a local inflammatory reaction that arises in response to radiation injury and may cause significant morbidity. This study aims to evaluate and compare the efficacy of bevacizumab and laser interstitial thermal therapy (LITT) in treating RN in patients with previously radiated central nervous system (CNS) neoplasms. Methods: PubMed, Cochrane, Scopus, and EMBASE databases were screened. Studies of patients with radiation necrosis from primary or secondary brain tumors were included. Indirect meta-analysis with random-effect modeling was performed to compare clinical and radiological outcomes. Results: Twenty-four studies were included with 210 patients in the bevacizumab group and 337 patients in the LITT group. Bevacizumab demonstrated symptomatic improvement/stability in 87.7% of cases, radiological improvement/stability in 86.2%, and steroid wean-off in 45%. LITT exhibited symptomatic improvement/stability in 71.2%, radiological improvement/stability in 64.7%, and steroid wean-off in 62.4%. Comparative analysis revealed statistically significant differences favoring bevacizumab in symptomatic improvement/stability (p = 0.02), while no significant differences were observed in radiological improvement/stability (p = 0.27) or steroid wean-off (p = 0.90). The rates of adverse reactions were 11.2% for bevacizumab and 14.9% for LITT (p = 0.66), with the majority being grade 2 or lower (72.2% for bevacizumab and 62.5% for LITT). Conclusion: Both bevacizumab and LITT exhibited favorable clinical and radiological outcomes in managing RN. Bevacizumab was found to be associated with better symptomatic control compared to LITT. Patient-, diagnosis- and lesion-related factors should be considered when choosing the ideal treatment modality for RN to enhance overall patient outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Laser Interstitial Thermotherapy (LITT) in Recurrent Glioblastoma: What Window of Opportunity for This Treatment?
- Author
-
Morello, Alberto, Bianconi, Andrea, Rizzo, Francesca, Bellomo, Jacopo, Meyer, Anna Cristina, Garbossa, Diego, Regli, Luca, and Cofano, Fabio
- Subjects
THERMOTHERAPY ,GLIOBLASTOMA multiforme ,INTRACRANIAL tumors ,LASERS ,SURGERY safety measures ,RADIOTHERAPY - Abstract
Laser Interstitial Thermotherapy is a minimally invasive treatment option in neurosurgery for intracranial tumors, including recurrent gliomas. The technique employs the thermal ablation of target tissue to achieve tumor control with real-time monitoring of the extent by magnetic resonance thermometry, allowing targeted thermal injury to the lesion. Laser Interstitial Thermotherapy has gained interest as a treatment option for recurrent gliomas due to its minimally invasive nature, shorter recovery times, ability to be used even in patients with numerous comorbidities, and potential to provide local tumor control. It can be used as a standalone treatment or combined with other therapies, such as chemotherapy or radiation therapy. We describe the most recent updates regarding several studies and case reports that have evaluated the efficacy and safety of Laser Interstitial Thermotherapy for recurrent gliomas. These studies have reported different outcomes, with some demonstrating promising results in terms of tumor control and patient survival, while others have shown mixed outcomes. The success of Laser Interstitial Thermotherapy depends on various factors, including tumor characteristics, patient selection, and the experience of the surgical team, but the future direction of treatment of recurrent gliomas will include a combined approach, comprising Laser Interstitial Thermotherapy, particularly in deep-seated brain regions. Well-designed prospective studies will be needed to establish with certainty the role of Laser Interstitial Thermotherapy in the treatment of recurrent glioma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Radiotherapy Induced Central Nervous System Toxicity
- Author
-
Munshi, Anusheel, Sarkar, Biplab, Pandey, Vikas, Sonkar, Deepak Raj, Sood Sharma, Kanika, editor, Chanana, Raajit, editor, and Sood, Gaurav, editor
- Published
- 2024
- Full Text
- View/download PDF
16. Management of CNS Tumors (General Principles)
- Author
-
Mubarak, Mohamed J., Al-Dhahir, Mohammed A., Salih, Hayder R., Ismail, Mustafa, Arnaout, Mohamed M., Hoz, Samer S., Hoz, Samer S., editor, Atallah, Oday, editor, Ma, Li, editor, Aljuboori, Zaid, editor, Sharma, Mayur, editor, Ismail, Mustafa, editor, and Delawan, Maliya, editor
- Published
- 2024
- Full Text
- View/download PDF
17. Retrospective examination of pseudoprogression in IDH mutant gliomas
- Author
-
Wetzel, Ethan A, Farrell, Matthew J, Eldred, Blaine SC, Liu, Vicki, Saha, Ishan, Rinonos, Serendipity Zapanta, Prins, Terry, Li, Tie, Cao, Minsong, Hegde, John, Kaprealian, Tania, Khanlou, Negar, Liau, Linda M, Nghiemphu, Phioanh Leia, Cloughesy, Timothy Francis, Chong, Robert A, Ellingson, Benjamin M, and Lai, Albert
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Research ,Rare Diseases ,Neurosciences ,Brain Cancer ,Brain Disorders ,contrast enhancement ,glioma ,IDH1 ,2 ,pseudoprogression ,radiation necrosis ,IDH1/2 - Abstract
BackgroundTumor surveillance of isocitrate dehydrogenase (IDH) mutant gliomas is accomplished via serial contrast MRI. When new contrast enhancement (CEnew) is detected during postsurgical surveillance, clinicians must assess whether CEnew indicates pseudoprogression (PsP) or tumor progression (TP). PsP has been better studied in IDH wild-type glioblastoma but has not been well characterized in IDH mutant gliomas. We conducted a retrospective study evaluating the incidence, predictors, natural history, and survival of PsP patients in a large cohort of IDH mutant glioma patients treated at a single institution.MethodsWe identified 587 IDH mutant glioma patients treated at UCLA. We directly inspected MRI images and radiology reports to identify CEnew and categorized CEnew into TP or PsP using MRI or histopathology.ResultsFifty-six percent of patients developed CEnew (326/587); of these, 92/326 patients (28% of CEnew; 16% of all) developed PsP and 179/326 (55%) developed TP. All PsP patients had prior radiation, chemotherapy, or chemoradiotherapy. PsP was associated with longer overall survival (OS) versus TP patients and similar OS versus no CEnew. PsP differs from TP based on earlier time of onset (median 5.8 vs 17.4 months from treatment, P < .0001) and MRI features that include punctate enhancement and enhancement location.ConclusionPsP patients represented 28% of CEnew patients and 16% of all patients; PsP patients demonstrated superior outcomes to TP patients, and equivalent survival to patients without CEnew. PsP persists for
- Published
- 2023
18. Efficacy of laser interstitial thermal therapy for biopsy-proven radiation necrosis in radiographically recurrent brain metastases
- Author
-
Chan, Michael, Tatter, Steven, Chiang, Veronica, Fecci, Peter, Strowd, Roy, Prabhu, Sujit, Hadjipanayis, Constantinos, Kirkpatrick, John, Sun, David, Sinicrope, Kaylyn, Mohammadi, Alireza M, Sevak, Parag, Abram, Steven, Kim, Albert H, Leuthardt, Eric, Chao, Samuel, Phillips, John, Lacroix, Michel, Williams, Brian, Placantonakis, Dimitris, Silverman, Joshua, Baumgartner, James, Piccioni, David, and Laxton, Adrian
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Brain Disorders ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,brain metastasis ,Laser interstitial thermal therapy ,radiographic progression ,radiation necrosis ,stereotactic laser ablation - Abstract
BackgroundLaser interstitial thermal therapy (LITT) in the setting of post-SRS radiation necrosis (RN) for patients with brain metastases has growing evidence for efficacy. However, questions remain regarding hospitalization, local control, symptom control, and concurrent use of therapies.MethodsDemographics, intraprocedural data, safety, Karnofsky performance status (KPS), and survival data were prospectively collected and then analyzed on patients who consented between 2016-2020 and who were undergoing LITT for biopsy-proven RN at one of 14 US centers. Data were monitored for accuracy. Statistical analysis included individual variable summaries, multivariable Fine and Gray analysis, and Kaplan-Meier estimated survival.ResultsNinety patients met the inclusion criteria. Four patients underwent 2 ablations on the same day. Median hospitalization time was 32.5 hours. The median time to corticosteroid cessation after LITT was 13.0 days (0.0, 1229.0) and cumulative incidence of lesional progression was 19% at 1 year. Median post-procedure overall survival was 2.55 years [1.66, infinity] and 77.1% at one year as estimated by KaplanMeier. Median KPS remained at 80 through 2-year follow-up. Seizure prevalence was 12% within 1-month post-LITT and 7.9% at 3 months; down from 34.4% within 60-day prior to procedure.ConclusionsLITT for RN was not only again found to be safe with low patient morbidity but was also a highly effective treatment for RN for both local control and symptom management (including seizures). In addition to averting expected neurological death, LITT facilitates ongoing systemic therapy (in particular immunotherapy) by enabling the rapid cessation of steroids, thereby facilitating maximal possible survival for these patients.
- Published
- 2023
19. Evaluating the Efficacy of Perfusion MRI and Conventional MRI in Distinguishing Recurrent Cerebral Metastasis from Brain Radiation Necrosis.
- Author
-
Schack, Anders, Aunan-Diop, Jan Saip, Gerhardt, Frederik A., Pedersen, Christian Bonde, Halle, Bo, Kofoed, Mikkel S., Markovic, Ljubo, Wirenfeldt, Martin, and Poulsen, Frantz Rom
- Subjects
- *
SURGICAL excision , *MAGNETIC resonance imaging , *PERFUSION , *NECROSIS , *BLOOD volume , *RADIATION - Abstract
Differentiating recurrent cerebral metastasis (CM) from brain radiation necrosis (BRN) is pivotal for guiding appropriate treatment and prognostication. Despite advances in imaging techniques, however, accurately distinguishing these conditions non-invasively is still challenging. This single-center retrospective study reviewed 32 cases (28 patients) with confirmed cerebral metastases who underwent surgical excision of lesions initially diagnosed by MRI and/or MR perfusion scans from 1 January 2015 to 30 September 2020. Diagnostic accuracy was assessed by comparing imaging findings with postoperative histopathology. Conventional MRI accurately identified recurrent CM in 75% of cases. MR perfusion scans showed significantly higher mean maximum relative cerebral blood volume (max. rCBV) in metastasis cases, indicating its potential as a discriminative biomarker. No single imaging modality could definitively distinguish CM from BRN. Survival analysis revealed gender as the only significant factor affecting overall survival, with no significant survival difference observed between patients with CM and BRN after controlling for confounding factors. This study underscores the limitations of both conventional MRI and MR perfusion scans in differentiating recurrent CM from BRN. Histopathological examination remains essential for accurate diagnosis. Further research is needed to improve the reliability of non-invasive imaging and to guide the management of patients with these post-radiation events. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Deuterium Magnetic Resonance Spectroscopy Quantifies Tumor Fraction in a Mouse Model of a Mixed Radiation Necrosis / GL261-Glioblastoma Lesion.
- Author
-
Song, Kyu-Ho, Ge, Xia, Engelbach, John, Rich, Keith M., Ackerman, Joseph J. H., and Garbow, Joel R.
- Subjects
- *
NUCLEAR magnetic resonance spectroscopy , *LABORATORY mice , *ANIMAL disease models , *DEUTERIUM , *WARBURG Effect (Oncology) , *MAGNETIZATION transfer , *LACTATES , *RADIOACTIVE tracers - Abstract
Purpose: Distinguishing recurrent brain tumor from treatment effects, including late time-to-onset radiation necrosis (RN), presents an on-going challenge in post-treatment imaging of neuro-oncology patients. Experiments were performed in a novel mouse model that recapitulates the relevant clinical histologic features of recurrent glioblastoma growing in a RN environment, the mixed tumor/RN model. The goal of this work was to apply single-voxel deuterium (2H) magnetic resonance spectroscopy (MRS), in concert with administration of deuterated glucose, to determine if the metabolic signature of aerobic glycolysis (Warburg effect: glucose → lactate in the presence of O2), a distinguishing characteristic of proliferating tumor, provides a quantitative readout of the tumor fraction (percent) in a mixed tumor/RN lesion. Procedures: 2H MRS employed the SPin-ECho full-Intensity Acquired Localized (SPECIAL) MRS pulse sequence and outer volume suppression at 11.74 T. For each subject, a single 2H MRS voxel was placed over the mixed lesion as defined by contrast enhanced (CE) 1H T1-weighted MRI. Following intravenous administration of [6,6-2H2]glucose (Glc), 2H MRS monitored the glycolytic conversion to [3,3-2H2]lactate (Lac) and glutamate + glutamine (Glu + Gln = Glx). Results: Based on previous work, the tumor fraction of the mixed lesion was quantified as the ratio of tumor volume, defined by 1H magnetization transfer experiments, vs. the total mixed-lesion volume. Metabolite 2H MR spectral-amplitude values were converted to metabolite concentrations using the natural-abundance semi-heavy water (1HO2H) resonance as an internal concentration standard. The 2H MR-determined [Lac] / [Glx] ratio was strongly linearly correlated with tumor fraction in the mixed lesion (n = 9), Pearson's r = 0.87, and 77% of the variation in the [Lac] / [Glx] ratio was due to tumor percent r2 = 0.77. Conclusions: This preclinical study supports the proposal that 2H MR could occupy a well-defined secondary role when standard-of-care 1H imaging is non-diagnostic regarding tumor presence and/or response to therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. MRI Treatment Response Assessment Maps (TRAMs) for differentiating recurrent glioblastoma from radiation necrosis.
- Author
-
Müller, Sebastian Johannes, Khadhraoui, Eya, Ganslandt, Oliver, Henkes, Hans, and Gihr, Georg Alexander
- Abstract
Background: MRI treatment response assessment maps (TRAMs) were introduced to distinguish recurrent malignant glioma from therapy related changes. TRAMs are calculated with two contrast-enhanced T1-weighted sequences and reflect the "late" wash-out (or contrast clearance) and wash-in of gadolinium. Vital tumor cells are assumed to produce a wash-out because of their high turnover rate and the associated hypervascularization, whereas contrast medium slowly accumulates in scar tissue. To examine the real value of this method, we compared TRAMs with the pathology findings obtained after a second biopsy or surgery when recurrence was suspected. Methods: We retrospectively evaluated TRAMs in adult patients with histologically demonstrated glioblastoma, contrast-enhancing tissue and a pre-operative MRI between January 1, 2017, and December 31, 2022. Only patients with a second biopsy or surgery were evaluated. Volumes of the residual tumor, contrast clearance and contrast accumulation before the second surgery were analyzed. Results: Among 339 patients with mGBM who underwent MRI, we identified 29 repeated surgeries/biopsies in 27 patients 59 ± 12 (mean ± standard deviation) years of age. Twenty-eight biopsies were from patients with recurrent glioblastoma histology, and only one was from a patient with radiation necrosis. We volumetrically evaluated the 29 pre-surgery TRAMs. In recurrent glioblastoma, the ratio of wash-out volume to tumor volume was 36 ± 17% (range 1–73%), and the ratio of the wash-out volume to the sum of wash-out and wash-in volumes was 48 ± 21% (range 22–92%). For the one biopsy with radiation necrosis, the ratios were 42% and 54%, respectively. Conclusions: Typical recurrent glioblastoma shows a > 20%ratio of the wash-out volume to the sum of wash-out and wash-in volumes. The one biopsy with radiation necrosis indicated that such necrosis can also produce high wash-out in individual cases. Nevertheless, the additional information provided by TRAMs increases the reliability of diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis (DYNDOPATEP)
- Published
- 2023
23. The use of MR perfusion parameters in differentiation between glioblastoma recurrence and radiation necrosis
- Author
-
Barbara Bobek-Billewicz, Sylwia Heinze, Aleksandra Awramienko-Wloczek, Krzysztof Majchrzak, Elzbieta Nowicka, and Anna Hebda
- Subjects
head ,magnetic resonance ,radiation necrosis ,glioblastoma ,magnetic resonance perfusion ,Medicine - Published
- 2023
- Full Text
- View/download PDF
24. Histopathologically confirmed radiation-induced damage of the brain – an in-depth analysis of radiation parameters and spatio-temporal occurrence
- Author
-
Mario R. P. Kossmann, Felix Ehret, Siyer Roohani, Sebastian F. Winter, Pirus Ghadjar, Güliz Acker, Carolin Senger, Simone Schmid, Daniel Zips, and David Kaul
- Subjects
Radiation necrosis ,Radionecrosis ,Pseudoprogression ,Subventricular zone ,Heatmap ,Frequency map ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Radiation-induced damage (RID) after radiotherapy (RT) of primary brain tumors and metastases can be challenging to clinico-radiographically distinguish from tumor progression. RID includes pseudoprogression and radiation necrosis; the latter being irreversible and often associated with severe symptoms. While histopathology constitutes the diagnostic gold standard, biopsy-controlled clinical studies investigating RID remain limited. Whether certain brain areas are potentially more vulnerable to RID remains an area of active investigation. Here, we analyze histopathologically confirmed cases of RID in relation to the temporal and spatial dose distribution. Methods Histopathologically confirmed cases of RID after photon-based RT for primary or secondary central nervous system malignancies were included. Demographic, clinical, and dosimetric data were collected from patient records and treatment planning systems. We calculated the equivalent dose in 2 Gy fractions (EQD22) and the biologically effective dose (BED2) for normal brain tissue (α/β ratio of 2 Gy) and analyzed the spatial and temporal distribution using frequency maps. Results Thirty-three patients were identified. High-grade glioma patients (n = 18) mostly received one normofractionated RT series (median cumulative EQD22 60 Gy) to a large planning target volume (PTV) (median 203.9 ccm) before diagnosis of RID. Despite the low EQD22 and BED2, three patients with an accelerated hyperfractionated RT developed RID. In contrast, brain metastases patients (n = 15; 16 RID lesions) were often treated with two or more RT courses and with radiosurgery or fractionated stereotactic RT, resulting in a higher cumulative EQD22 (median 162.4 Gy), to a small PTV (median 6.7 ccm). All (n = 34) RID lesions occurred within the PTV of at least one of the preceding RT courses. RID in the high-grade glioma group showed a frontotemporal distribution pattern, whereas, in metastatic patients, RID was observed throughout the brain with highest density in the parietal lobe. The cumulative EQD22 was significantly lower in RID lesions that involved the subventricular zone (SVZ) than in lesions without SVZ involvement (median 60 Gy vs. 141 Gy, p = 0.01). Conclusions Accelerated hyperfractionated RT can lead to RID despite computationally low EQD22 and BED2 in high-grade glioma patients. The anatomical location of RID corresponded to the general tumor distribution of gliomas and metastases. The SVZ might be a particularly vulnerable area.
- Published
- 2023
- Full Text
- View/download PDF
25. Histopathological correlation of brain tumor recurrence vs. radiation effect post-radiosurgery as detected by MRI contrast clearance analysis: a validation study
- Author
-
Goulenko, Victor, Madhugiri, Venkatesh Shankar, Bregy, Amade, Recker, Matthew, Lipinski, Lindsay, Fabiano, Andrew, Fenstermaker, Robert, Plunkett, Robert, Abad, Ajay, Belal, Ahmed, Alberico, Ronald, Qiu, Jingxin, and Prasad, Dheerendra
- Published
- 2024
- Full Text
- View/download PDF
26. Impact of concurrent antibody–drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study
- Author
-
Koide, Yutaro, Nagai, Naoya, Adachi, Sou, Ito, Masayuki, Kawamura, Mariko, Ito, Makoto, Ito, Fumitaka, Shindo, Yurika, Aoyama, Takahiro, Shimizu, Hidetoshi, Hashimoto, Shingo, Tachibana, Hiroyuki, and Kodaira, Takeshi
- Published
- 2024
- Full Text
- View/download PDF
27. Delayed Imaging Changes 18 Months or Longer After Stereotactic Radiosurgery for Brain Metastases: Necrosis or Progression.
- Author
-
Williams, Michelle M., Sohrabi, Arian K., Kittel, Carol A., White, Jaclyn J., Cramer, Christina K., Lanier, Claire M., Ruiz, Jimmy, Xing, Fei, Li, Wencheng, Whitlow, Christopher T., Tatter, Stephen B., Chan, Michael D., and Laxton, Adrian W.
- Subjects
- *
STEREOTACTIC radiosurgery , *BRAIN metastasis , *CANCER invasiveness , *BRAIN damage , *NECROSIS - Abstract
Imaging changes after stereotactic radiosurgery (SRS) can occur for years after treatment, although the available data on the incidence of tumor progression and adverse radiation effects (ARE) are generally limited to the first 2 years after treatment. A single-institution retrospective review was conducted of patients who had >18 months of imaging follow-up available. Patients who had ≥1 metastatic brain lesions treated with Gamma Knife SRS were assessed for the time to radiographic progression. Those with progression ≥18 months after the initial treatment were included in the present study. The lesions that progressed were characterized as either ARE or tumor progression based on the tissue diagnosis or imaging characteristics over time. The cumulative incidence of delayed imaging radiographic progression was 35% at 5 years after the initial SRS. The cumulative incidence curves of the time to radiographic progression for lesions determined to be ARE and lesions determined to be tumor progression were not significantly different statistically. The cumulative incidence of delayed ARE and delayed tumor progression was 17% and 16% at 5 years, respectively. Multivariate analysis indicated that the number of metastatic brain lesions present at the initial SRS was the only factor associated with late radiographic progression. The timing of late radiographic progression does not differ between ARE and tumor progression. The number of metastatic brain lesions at the initial SRS is a risk factor for late radiographic progression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. High Radiation Dose to the Fornix Causes Symptomatic Radiation Necrosis in Patients with Anaplastic Oligodendroglioma.
- Author
-
Tae Hyung Kim, Jaeho Cho, Seok-Gu Kang, Ju Hyung Moon, Chang-Ok Suh, Yae Won Park, Jong Hee Chang, and Hong In Yoon
- Abstract
Purpose: Surgery, radiotherapy (RT), and chemotherapy have prolonged the survival of patients with anaplastic oligodendroglioma. However, whether RT induces long-term toxicity remains unknown. We analyzed the relationship between the RT dose to the fornix and symptomatic radiation necrosis (SRN). Materials and Methods: A total of 67 patients treated between 2009 and 2019 were analyzed. SRN was defined according to the following three criteria: 1) radiographic findings, 2) symptoms attributable to the lesion, and 3) treatment resulting in symptom improvement. Various contours, including the fornix, were delineated. Univariate and multivariate analyses of the relationship between RT dose and SRN, as well as receiver operating characteristic curve analysis for cut-off values, were performed. Results: The most common location was the frontal lobe (n=40, 60%). Gross total resection was performed in 38 patients (57%), and 42 patients (63%) received procarbazine, lomustine, and vincristine chemotherapy. With a median follow-up of 42 months, the median overall and progression-free survival was 74 months. Sixteen patients (24%) developed SRN. In multivariate analysis, age and maximum dose to the fornix were associated with the development of SRN. The cut-off values for the maximum dose to the fornix and age were 59 Gy (equivalent dose delivered in 2 Gy fractions) and 46 years, respectively. The rate of SRN was higher in patients whose maximum dose to the fornix was >59 Gy (13% vs. 43%, p=0.005). Conclusion: The maximum dose to the fornix was a significant factor for SRN development. While fornix sparing may help maintain neurocognitive function, additional studies are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Umbrella review and network meta-analysis of diagnostic imaging test accuracy studies in Differentiating between brain tumor progression versus pseudoprogression and radionecrosis.
- Author
-
Dagher, Richard, Gad, Mona, da Silva de Santana, Paloma, Sadeghi, Mohammad Amin, Yewedalsew, Selome F., Gujar, Sachin K., Yedavalli, Vivek, Köhler, Cristiano André, Khan, Majid, Tavora, Daniel Gurgel Fernandes, Kamson, David Olayinka, Sair, Haris I., and Luna, Licia P.
- Abstract
Purpose: In this study we gathered and analyzed the available evidence regarding 17 different imaging modalities and performed network meta-analysis to find the most effective modality for the differentiation between brain tumor recurrence and post-treatment radiation effects. Methods: We conducted a comprehensive systematic search on PubMed and Embase. The quality of eligible studies was assessed using the Assessment of Multiple Systematic Reviews-2 (AMSTAR-2) instrument. For each meta-analysis, we recalculated the effect size, sensitivity, specificity, positive and negative likelihood ratios, and diagnostic odds ratio from the individual study data provided in the original meta-analysis using a random-effects model. Imaging technique comparisons were then assessed using NMA. Ranking was assessed using the multidimensional scaling approach and by visually assessing surface under the cumulative ranking curves. Results: We identified 32 eligible studies. High confidence in the results was found in only one of them, with a substantial heterogeneity and small study effect in 21% and 9% of included meta-analysis respectively. Comparisons between MRS Cho/NAA, Cho/Cr, DWI, and DSC were most studied. Our analysis showed MRS (Cho/NAA) and 18F-DOPA PET displayed the highest sensitivity and negative likelihood ratios. 18-FET PET was ranked highest among the 17 studied techniques with statistical significance. APT MRI was the only non-nuclear imaging modality to rank higher than DSC, with statistical insignificance, however. Conclusion: The evidence regarding which imaging modality is best for the differentiation between radiation necrosis and post-treatment radiation effects is still inconclusive. Using NMA, our analysis ranked FET PET to be the best for such a task based on the available evidence. APT MRI showed promising results as a non-nuclear alternative. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Histopathologically confirmed radiation-induced damage of the brain – an in-depth analysis of radiation parameters and spatio-temporal occurrence.
- Author
-
Kossmann, Mario R. P., Ehret, Felix, Roohani, Siyer, Winter, Sebastian F., Ghadjar, Pirus, Acker, Güliz, Senger, Carolin, Schmid, Simone, Zips, Daniel, and Kaul, David
- Subjects
- *
BRAIN damage , *BRAIN tumors , *PARIETAL lobe , *CENTRAL nervous system , *RADIATION injuries , *CANCER invasiveness , *MEDICAL dosimetry - Abstract
Background: Radiation-induced damage (RID) after radiotherapy (RT) of primary brain tumors and metastases can be challenging to clinico-radiographically distinguish from tumor progression. RID includes pseudoprogression and radiation necrosis; the latter being irreversible and often associated with severe symptoms. While histopathology constitutes the diagnostic gold standard, biopsy-controlled clinical studies investigating RID remain limited. Whether certain brain areas are potentially more vulnerable to RID remains an area of active investigation. Here, we analyze histopathologically confirmed cases of RID in relation to the temporal and spatial dose distribution. Methods: Histopathologically confirmed cases of RID after photon-based RT for primary or secondary central nervous system malignancies were included. Demographic, clinical, and dosimetric data were collected from patient records and treatment planning systems. We calculated the equivalent dose in 2 Gy fractions (EQD22) and the biologically effective dose (BED2) for normal brain tissue (α/β ratio of 2 Gy) and analyzed the spatial and temporal distribution using frequency maps. Results: Thirty-three patients were identified. High-grade glioma patients (n = 18) mostly received one normofractionated RT series (median cumulative EQD22 60 Gy) to a large planning target volume (PTV) (median 203.9 ccm) before diagnosis of RID. Despite the low EQD22 and BED2, three patients with an accelerated hyperfractionated RT developed RID. In contrast, brain metastases patients (n = 15; 16 RID lesions) were often treated with two or more RT courses and with radiosurgery or fractionated stereotactic RT, resulting in a higher cumulative EQD22 (median 162.4 Gy), to a small PTV (median 6.7 ccm). All (n = 34) RID lesions occurred within the PTV of at least one of the preceding RT courses. RID in the high-grade glioma group showed a frontotemporal distribution pattern, whereas, in metastatic patients, RID was observed throughout the brain with highest density in the parietal lobe. The cumulative EQD22 was significantly lower in RID lesions that involved the subventricular zone (SVZ) than in lesions without SVZ involvement (median 60 Gy vs. 141 Gy, p = 0.01). Conclusions: Accelerated hyperfractionated RT can lead to RID despite computationally low EQD22 and BED2 in high-grade glioma patients. The anatomical location of RID corresponded to the general tumor distribution of gliomas and metastases. The SVZ might be a particularly vulnerable area. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. The impact of embolization on radiosurgery obliteration rates for brain arteriovenous malformations: a systematic review and meta‐analysis.
- Author
-
Chang, Henry, Silva, Michael A., Weng, John, Kovacevic, Jasmina, Luther, Evan, and Starke, Robert M.
- Abstract
There exists no consensus in the literature regarding the impact of pre-stereotactic radiosurgery (SRS) embolization on obliteration rates and clinical outcome after radiosurgery treatment of intracranial arteriovenous malformations (AVM). We performed a systematic review of four databases and included studies with at least 10 patients evaluating obliteration rates of intracranial AVMs treated with SRS alone (SRS cohort) and combined pre-SRS embolization followed by SRS (E + SRS cohort). Meta-analytic results were pooled together via random-effects models. A total of 43 studies, with 7103 patients, were included in our analysis. Among our included patients, complete obliteration was achieved in 51.5% (964/1871) of patients in the E + SRS cohort as compared to 61.5% (3217/5231) of patients in the SRS cohort. Meta-analysis of the pooled data revealed that obliteration was significantly lower in the E + SRS cohort (pooled OR = 0.64, 95% CI = 0.54–0.75, p < 0.0001). The use of pre-SRS embolization was significantly associated with lower AVM obliteration rates when compared to treatment with SRS alone. Our analysis seeks to provide a macroscopic insight into the complex interaction between pre-SRS embolization and brain AVM obliteration rates and prognosis. Pre-SRS embolization may still be beneficial in select patients, and further studies are needed to identify patients who benefit from neoadjuvant AVM embolization. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Pentoxifylline and Vitamin E Can Restrict Radiation Necrosis via Vascular Pathways, Experimental Study in an Animal Model.
- Author
-
Otluoglu, Gulden Demirci, Yılmaz, Baran, Ekinci, Gazanfer, Bayri, Yaşar, Bozkurt, Süheyla Uyar, and Dağçınar, Adnan
- Subjects
- *
VITAMIN E , *PENTOXIFYLLINE , *VASCULAR endothelial growth factors , *LABORATORY animals , *RADIOSURGERY , *BLOOD coagulation factor VIII - Abstract
Radiation necrosis (RN) is a long-term side effect of Gamma Knife stereotactic radiosurgery that may require surgical intervention. Pentoxifylline and vitamin E have previously been shown to be effective in the treatment of RN in the published literature, but there are no data on the prophylactic use of these molecules or, more importantly, whether prophylaxis is required. The iatrogenic RN model included 50 Sprague–Dawley rats of both sexes. There were 7 treatment subgroups established. Gamma–Plan 8.32 was used to plan after magnetic resonance scans were performed in a specially designed frame. The injection doses used in the treatment groups were vitamin E (30 mg/kg/day in a single dose) and pentoxifylline (50 mg/kg/day in 2 doses). Control magnetic resonance scans were performed at the end of a 16-week treatment, and the subjects were decapitated for pathological evaluations. The intensity of hypoxia - inducible factor 1α immunoreactivity is statistically significantly lower in the therapeutic vitamin E, prophylactic pentoxifylline and vitamin E, and therapeutic pentoxifylline and vitamin E groups than in the other groups. Similarly, the intensity of vascular endothelial growth factor immunoreactivity was reduced in the therapeutic vitamin E and prophylactic pentoxifylline and vitamin E treatment modality groups. When compared with other groups, the therapeutic pentoxifylline group had significantly fewer vascular endothelial growth factor-immunoreactive cells in the perinecrotic area, with an accompanying decreased contrast enhancement pattern. Both vitamin E and pentoxifylline are effective for the treatment and/or restriction of RN, either alone or in combination. The use of these molecules as a preventive measure did not outperform the therapeutic treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12)
- Author
-
Raphael Bodensohn, Daniel F. Fleischmann, Sebastian H. Maier, Vasiliki Anagnostatou, Sylvia Garny, Alexander Nitschmann, Marcel Büttner, Johannes Mücke, Stephan Schönecker, Kristian Unger, Elgin Hoffmann, Frank Paulsen, Daniela Thorwarth, Adrien Holzgreve, Nathalie L. Albert, Stefanie Corradini, Ghazaleh Tabatabai, Claus Belka, and Maximilian Niyazi
- Subjects
Glioblastoma ,Dose escalation ,FET PET ,Bevacizumab ,Radiation necrosis ,NTCP ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and purpose: The PRIDE trial (NOA-28; ARO-2022-12; NCT05871021) is scheduled to start recruitment in October 2023. Its primary objective is to enhance median overall survival (OS), compared to historical median OS rates, in patients with methylguanine methlyltransferase (MGMT) promotor unmethylated glioblastoma by incorporating isotoxic dose escalation to 75 Gy in 30 fractions. To achieve isotoxicity and counteract the elevated risk of radiation necrosis (RN) associated with dose-escalated regimens, the addition of protective concurrent bevacizumab (BEV) serves as an innovative approach. The current study aims to assess the dosimetric feasibility of the proposed concept. Materials and methods: A total of ten patients diagnosed with glioblastoma were included in this dosimetric analysis. Delineation of target volumes for the reference plans adhered to the ESTRO-EANO 2023 guideline. The experimental plans included an additional volume for the integrated boost. Additionally, the 60 Gy-volume was reduced by using a margin of 1.0 cm instead of 1.5 cm. To assess the risk of symptomatic RN, the Normal Tissue Complication Probability (NTCP) was calculated and compared between the reference and experimental plans. Results: Median NTCP of the reference plan (NTCPref) and of the experimental plan (NTCPex) were 0.24 (range 0.11–0.29) and 0.42 (range 0.18–0.54), respectively. NTCPex was a median of 1.77 (range 1.60–1.99) times as high as the NTXPref. In a logarithmic comparison, the risk of RN is enhanced by a factor of median 2.00 (range 1.66–2.35). The defined constraints for the organs at risk were feasible. Conclusion: When considering the potential protective effect of BEV, which we hypothesized might reduce the risk of RN by approximately two-fold, achieving isotoxicity with the proposed dose-escalated experimental plan for the PRIDE trial seems feasible.
- Published
- 2024
- Full Text
- View/download PDF
34. Predicting Adverse Radiation Effects in Brain Tumors After Stereotactic Radiotherapy With Deep Learning and Handcrafted Radiomics
- Author
-
Keek, Simon A, Beuque, Manon, Primakov, Sergey, Woodruff, Henry C, Chatterjee, Avishek, van Timmeren, Janita E, Vallières, Martin, Hendriks, Lizza EL, Kraft, Johannes, Andratschke, Nicolaus, Braunstein, Steve E, Morin, Olivier, and Lambin, Philippe
- Subjects
Patient Safety ,Neurosciences ,Cancer ,Good Health and Well Being ,brain metastases ,radiation necrosis ,deep learning ,artificial neural network ,radiomics ,MRI ,adverse radiation effects ,deep learning - artificial neural network ,Oncology and Carcinogenesis - Abstract
IntroductionThere is a cumulative risk of 20-40% of developing brain metastases (BM) in solid cancers. Stereotactic radiotherapy (SRT) enables the application of high focal doses of radiation to a volume and is often used for BM treatment. However, SRT can cause adverse radiation effects (ARE), such as radiation necrosis, which sometimes cause irreversible damage to the brain. It is therefore of clinical interest to identify patients at a high risk of developing ARE. We hypothesized that models trained with radiomics features, deep learning (DL) features, and patient characteristics or their combination can predict ARE risk in patients with BM before SRT.MethodsGadolinium-enhanced T1-weighted MRIs and characteristics from patients treated with SRT for BM were collected for a training and testing cohort (N = 1,404) and a validation cohort (N = 237) from a separate institute. From each lesion in the training set, radiomics features were extracted and used to train an extreme gradient boosting (XGBoost) model. A DL model was trained on the same cohort to make a separate prediction and to extract the last layer of features. Different models using XGBoost were built using only radiomics features, DL features, and patient characteristics or a combination of them. Evaluation was performed using the area under the curve (AUC) of the receiver operating characteristic curve on the external dataset. Predictions for individual lesions and per patient developing ARE were investigated.ResultsThe best-performing XGBoost model on a lesion level was trained on a combination of radiomics features and DL features (AUC of 0.71 and recall of 0.80). On a patient level, a combination of radiomics features, DL features, and patient characteristics obtained the best performance (AUC of 0.72 and recall of 0.84). The DL model achieved an AUC of 0.64 and recall of 0.85 per lesion and an AUC of 0.70 and recall of 0.60 per patient.ConclusionMachine learning models built on radiomics features and DL features extracted from BM combined with patient characteristics show potential to predict ARE at the patient and lesion levels. These models could be used in clinical decision making, informing patients on their risk of ARE and allowing physicians to opt for different therapies.
- Published
- 2022
35. Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI) (LIBERTI)
- Author
-
University of Kentucky and Shervin Dashti, MD, Principal Investigator
- Published
- 2022
36. Hybrid Positron Emission Tomography and Magnetic Resonance Imaging Guided Microsurgical Management of Glial Tumors: Case Series and Review of the Literature
- Author
-
Yusuf Sukru Caglar, Murat Buyuktepe, Emre Yagiz Sayaci, Ihsan Dogan, Melih Bozkurt, Elif Peker, Cigdem Soydal, Elgin Ozkan, and Nuriye Ozlem Kucuk
- Subjects
hybrid imaging ,magnetic resonance imaging ,positron emission tomography ,radiation necrosis ,recurrent glial tumor ,Medicine (General) ,R5-920 - Abstract
In this case series, we aimed to report our clinical experience with hybrid positron emission tomography (PET) and magnetic resonance imaging (MRI) navigation in the management of recurrent glial brain tumors. Consecutive recurrent neuroglial brain tumor patients who underwent PET/MRI at preoperative or intraoperative periods were included, whereas patients with non-glial intracranial tumors including metastasis, lymphoma and meningioma were excluded from the study. A total of eight patients (mean age 50.1 ± 11.0 years) with suspicion of recurrent glioma tumor were evaluated. Gross total tumor resection of the PET/MRI-positive area was achieved in seven patients, whereas one patient was diagnosed with radiation necrosis, and surgery was avoided. All patients survived at 1-year follow-up. Five (71.4%) of the recurrent patients remained free of recurrence for the entire follow-up period. Two patients with glioblastoma had tumor recurrence at the postoperative sixth and eighth months. According to our results, hybrid PET/MRI provides reliable and accurate information to distinguish recurrent glial tumor from radiation necrosis. With the help of this differential diagnosis, hybrid imaging may provide the gross total resection of recurrent tumors without harming eloquent brain areas.
- Published
- 2024
- Full Text
- View/download PDF
37. Tumor-Like Lesions
- Author
-
Lacruz, César R. and Lacruz, César R., editor
- Published
- 2023
- Full Text
- View/download PDF
38. Radiation Related Toxicities and Management
- Author
-
Hardy, Sara J., Milano, Michael T., Mohile, Nimish A., editor, and Thomas, Alissa A., editor
- Published
- 2023
- Full Text
- View/download PDF
39. Internal Capsule Arteriovenous Malformation (AVM)
- Author
-
Abdelaziz, Osama S., De Salles, Antonio A. F., Abdelaziz, Osama S., and De Salles, Antonio A.F.
- Published
- 2023
- Full Text
- View/download PDF
40. Thalamic Arteriovenous Malformation (AVM)
- Author
-
Abdelaziz, Osama S., De Salles, Antonio A. F., Abdelaziz, Osama S., and De Salles, Antonio A.F.
- Published
- 2023
- Full Text
- View/download PDF
41. Solitary Brain Metastasis
- Author
-
Abdelaziz, Osama S., De Salles, Antonio A. F., Abdelaziz, Osama S., and De Salles, Antonio A.F.
- Published
- 2023
- Full Text
- View/download PDF
42. Anterior Cranial Fossa Meningioma
- Author
-
Abdelaziz, Osama S., De Salles, Antonio A. F., Abdelaziz, Osama S., and De Salles, Antonio A.F.
- Published
- 2023
- Full Text
- View/download PDF
43. Complicated Brain Arteriovenous Malformation (AVM) with Radiation Necrosis
- Author
-
Abdelaziz, Osama S., De Salles, Antonio A. F., Abdelaziz, Osama S., and De Salles, Antonio A.F.
- Published
- 2023
- Full Text
- View/download PDF
44. Cerebral Parenchymal Arteriovenous Malformation (AVM)
- Author
-
Abdelaziz, Osama S., De Salles, Antonio A. F., Abdelaziz, Osama S., and De Salles, Antonio A.F.
- Published
- 2023
- Full Text
- View/download PDF
45. Anti-angiogenic therapies in the management of glioblastoma.
- Author
-
Schulte, Jessica, Aghi, Manish, and Taylor, Jennie
- Subjects
Brain tumor ,angiogenesis ,glioblastoma (GBM) ,radiation necrosis ,resistance ,vascular endothelial growth factor (VEGF) ,Brain Neoplasms ,Glioblastoma ,Glioma ,Humans ,Neovascularization ,Pathologic ,Vascular Endothelial Growth Factor A - Abstract
Angiogenesis is a central feature of glioblastoma (GBM), with contribution from several mechanisms and signaling pathways to produce an irregular, poorly constructed, and poorly connected tumor vasculature. Targeting angiogenesis has been efficacious for disease control in other cancers, and given the (I) highly vascularized environment in GBM and (II) correlation between glioma grade and prognosis, angiogenesis became a prime target of therapy in GBM as well. Here, we discuss the therapies developed to target these pathways including vascular endothelial growth factor (VEGF) signaling, mechanisms of tumor resistance to these drugs in the context of disease progression, and the evolving role of anti-angiogenic therapy in GBM.
- Published
- 2021
46. RADIATION NECROSIS AFTER CAVERNOMA RADIOSURGERY SIMULATING BRAIN HIGH-GRADE GLIOMA – A CASE REPORT AND REVIEW OF THE LITERATURE
- Author
-
Radoslav Georgiev
- Subjects
radiation necrosis ,radiosurgery ,cavernoma ,high-grade glioma ,mri ,Dentistry ,RK1-715 ,Medicine (General) ,R5-920 - Abstract
We report a 62-year-old female patient who came to our institution due to pain and limited movements in the neck area, nausea, and headache. The magnetic resonance imaging (MRI) revealed a single larger and two smaller lesions with the appearance of cavernomas in the left parietal brain region. The patient was consulted with a neurosurgeon and was judged to be inoperable. Radiosurgery was performed in the cavernoma with a total focal dose of 15Gy. 11 months after the radiotherapy, during a routine follow-up MRI scan, a tumor-like lesion with extensive perifocal edema and midline dislocation, with heterogenous structure and ring-like enhancement was reported in the left parietal brain region. After follow-up for 15 months, the last MRI showed almost complete reverse development of the described lesion, with marked reduction of volume, edema, and contrast enhancement. Along with MRI features of the lesion, some of which overlap with high-grade glioma characteristics, the evolution of the lesion is in favor of a radiation necrosis zone.
- Published
- 2023
- Full Text
- View/download PDF
47. Radiosurgery for Brain Metastases: Challenges in Imaging Interpretation after Treatment.
- Author
-
Romano, Andrea, Moltoni, Giulia, Blandino, Antonella, Palizzi, Serena, Romano, Allegra, de Rosa, Giulia, De Blasi Palma, Lara, Monopoli, Cristiana, Guarnera, Alessia, Minniti, Giuseppe, and Bozzao, Alessandro
- Subjects
- *
METASTASIS , *MAGNETIC resonance imaging , *RADIATION , *BRAIN tumors , *DIAGNOSTIC imaging , *TREATMENT effectiveness , *RADIOSURGERY , *IMMUNOTHERAPY , *NECROSIS , *EVALUATION - Abstract
Simple Summary: Stereotactic radiosurgery is one of the main treatments for patients with brain metastases, with important achievements in terms of patient prognosis. Nevertheless, radiation treatment may induce brain changes, visible in neuroimaging, that are often difficult to distinguish from progressive disease. This review aims to provide an update on the innovative neuroimaging modalities to study brain changes after stereotactic radiosurgery, focusing on the differential diagnosis between the presence of disease and post-treatment effects. Stereotactic radiosurgery (SRS) has transformed the management of brain metastases by achieving local tumor control, reducing toxicity, and minimizing the need for whole-brain radiation therapy (WBRT). This review specifically investigates radiation-induced changes in patients treated for metastasis, highlighting the crucial role of magnetic resonance imaging (MRI) in the evaluation of treatment response, both at very early and late stages. The primary objective of the review is to evaluate the most effective imaging techniques for assessing radiation-induced changes and distinguishing them from tumor growth. The limitations of conventional imaging methods, which rely on size measurements, dimensional criteria, and contrast enhancement patterns, are critically evaluated. In addition, it has been investigated the potential of advanced imaging modalities to offer a more precise and comprehensive evaluation of treatment response. Finally, an overview of the relevant literature concerning the interpretation of brain changes in patients undergoing immunotherapies is provided. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. Tumor Location Impacts the Development of Radiation Necrosis in Benign Intracranial Tumors.
- Author
-
Demetz, Matthias, Mangesius, Julian, Krigers, Aleksandrs, Nevinny-Stickel, Meinhard, Thomé, Claudius, Freyschlag, Christian F., and Kerschbaumer, Johannes
- Subjects
- *
MULTIVARIATE analysis , *RETROSPECTIVE studies , *ACQUISITION of data , *MAGNETIC resonance imaging , *REGRESSION analysis , *BRAIN tumors , *RISK assessment , *COMPARATIVE studies , *TREATMENT effectiveness , *CANCER patients , *MEDICAL records , *DESCRIPTIVE statistics , *RADIATION injuries , *RADIOSURGERY , *SKULL tumors , *NECROSIS , *PROPORTIONAL hazards models , *DISEASE risk factors - Abstract
Simple Summary: The impact of tumor location on the development of radiation necrosis is still unclear. We evaluated 205 patients with benign intracranial tumors, who underwent stereotactic radiosurgery. A total of 15.6% developed radiation necrosis after a median of 10 months. According to our data, tumors located at the skull base showed a significantly lower risk of radiation necrosis (HR 0.252, p < 0.001). The data from this study suggest that the tumor location at the skull base can affect the development of radiation necrosis in benign intracranial neoplasms. Background: Radiation necrosis (RN) is a possible late complication of stereotactic radiosurgery (SRS), but only a few risk factors are known. The aim of this study was to assess tumor location in correlation to the development of radiation necrosis for skull base (SB) and non-skull base tumors. Methods: All patients treated with radiosurgery for benign neoplasms (2004–2020) were retrospectively evaluated. The clinical, imaging and medication data were obtained and the largest axial tumor diameter was determined using MRI scans in T1-weighted imaging with gadolinium. The diagnosis of RN was established using imaging parameters. Patients with tumors located at the skull base were compared to patients with tumors in non-skull base locations. Results: 205 patients could be included. Overall, 157 tumors (76.6%) were located at the SB and compared to 48 (23.4%) non-SB tumors. Among SB tumors, the most common were vestibular schwannomas (125 cases) and meningiomas (21 cases). In total, 32 (15.6%) patients developed RN after a median of 10 (IqR 5–12) months. Moreover, 62 patients (30.2%) had already undergone at least one surgical resection. In multivariate Cox regression, SB tumors showed a significantly lower risk of radiation necrosis with a Hazard Ratio (HR) of 0.252, p < 0.001, independently of the applied radiation dose. Furthermore, higher radiation doses had a significant impact on the occurrence of RN (HR 1.372, p = 0.002). Conclusions: The risk for the development of RN for SB tumors appears to be low but should not be underestimated. No difference was found between recurrent tumors and newly diagnosed tumors, which may support the value of radiosurgical treatment for patients with recurrent SB tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. LITT for biopsy proven radiation necrosis: A qualitative systematic review.
- Author
-
Cuschieri, Andrea, Borg, Mariah, Levinskaia, Eliza, and Zammit, Christian
- Abstract
• The incidence of radiation necrosis is increasing, necessitating more efficacious treatment modalities. • LITT has emerged as a promising second-line treatment against RN, with significant advantages namely same-day biopsy and improved patient outcomes improved lesion control. • The incongruence in outcome reporting adds to the uncertainty in adopting LITT as a novel approach as a possible surgical intervention. • Future studies should closely mirror results reported by published literature, while addressing their limitations, to facilitate the generalisability of patient outcomes across studies. With the widespread use of stereotactic radiosurgery (SRS), post-radiation treatment effects (PTREs) are increasing in prevalence. Radiation necrosis (RN) is a serious PTRE which carries a poor prognosis. Since 2012, laser interstitial thermal therapy (LITT) has been used to treat RN. However, reviews have attempting to generalise the efficacy of LITT against biopsy-proven RN are limited. In this systematic review, patient demographic characteristics and post-LITT clinical outcomes are characterised. A systematic literature search was conducted in four major databases for cohort studies and case reports published between 2012 and 2022, following the PRISMA 2020 checklist. Data was extracted and descriptively analysed. Quality of reporting was assessed using the PROCESS criteria and reporting bias was evaluated using the ROBINS-I scoring system. Eleven studies met our inclusion criteria, with an overall moderate risk of reporting bias being observed. Mean pre-LITT target lesion volume was 6.75 cm
3 , and was independent of gender, time since SRS, age and number of interventions prior to LITT. LITT is a versatile treatment option which may be used to treat a vast range of patients with refractory biopsy-proven RN. However, neurosurgeons should exercise caution when selecting patients for LITT due to insufficient data on the treatment's efficacy against biopsy-proven RN. This warrants further studies to unequivocally determine the safety and clinical outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
50. The use of MR perfusion parameters in differentiation between glioblastoma recurrence and radiation necrosis.
- Author
-
Bobek-Billewicz, Barbara, Heinze, Sylwia, Awramienko-Wloczek, Aleksandra, Majchrzak, Krzysztof, Nowicka, Elzbieta, and Hebda, Anna
- Abstract
Introduction: This study focuses on the challenge of distinguishing between tumour recurrence and radiation necrosis in glioma treatment using magnetic resonance imaging (MRI). Currently, accurate differentiation is possible only through surgical biopsy, which is invasive and may cause additional damage. The study explores non-invasive methods using dynamic susceptibility contrast (DSC) MR perfusion with parameters like relative peak height (rPH) and relative percentage of signal-intensity recovery (rPSR). Material and methods: Among retrospectively evaluated patients (multicentre study) with an initial diagnosis of the primary and secondary brain tumour, 47 met the inclusion criteria and were divided into two groups, the recurrent glioblastoma (GBM) WHO IV group and the radiation necrosis group, based on MRI of the brain. All patients enrolled into the recurrent GBM group had a second surgical intervention. Results: Mean, minimum and maximum rPH values were significantly higher in the recurrent GBM group than in the radiation necrosis group (p < 0.001), while rPSR values were lower in the recurrent GBM group than in the radiation necrosis group (p = 0.011 and p = 0.012). Discussion: This study investigates the use of MR perfusion curve characteristics to differentiate between radiation necrosis and glioblastoma recurrence in post-treatment brain tumours. MR perfusion shows promising potential for distinguishing between the two conditions, but it also has certain limitations. Despite challenges in finding a sufficient cohort size, the study demonstrates significant differences in MR perfusion parameters between radiation necrosis and GBM recurrence. Conclusions: The results demonstrate the potential usefulness of these DSC perfusion parameters in discriminating between glioblastoma recurrence and radiation necrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.